CND Life Sciences’ Innovative Biomarker Services in Clinical Trials
In the field of medical technology, CND Life Sciences, Inc. has emerged as a pioneering force with its Syn-One Biomarker Services. These services have recently been applied in an exploratory context within a Phase 2 clinical trial conducted by ABLi Therapeutics. The study aimed to investigate risvodetinib, a promising drug candidate for Parkinson's disease, focusing on its effects on phosphorylated alpha-synuclein.
Understanding the Importance of Biomarker Services
Biopharmaceutical companies are continuously in search of tools that enable them to determine the efficacy of their treatments and ensure they select the right patients for their clinical trials. CND's Syn-One Biomarker Services are designed to quantify and visualize reductions in abnormal protein deposits like alpha-synuclein, specifically in cutaneous nerves. This pivotal feature allows researchers to track disease progression and responses to treatment with greater precision.
A Breakthrough in Parkinson's Disease Treatment
Recently, results from ABLi's Phase 2 trial, referred to as the "201 Trial", showcased the impact of CND's biomarker services. The trial aimed to measure changes in phosphorylated alpha-synuclein over time, with significant results presented by ABLi Therapeutics' Chairman and CEO, Dr. Milton Werner. These findings were shared during a keynote session at an important Movement Disorders Society Annual Congress.
Results of the Trial and Implications for Future Research
In the 201 Trial, an exploratory analysis was performed utilizing CND's services to track changes in phosphorylated alpha-synuclein in biopsy samples taken from 36 participants. Notably, the analysis revealed a decrease in phosphorylated alpha-synuclein among subjects treated with risvodetinib. This preliminary data provides optimism about the potential roles of CND's biomarker services in both measuring and influencing treatment pathways for Parkinson's disease and related disorders.
Innovative Technology Driving Research Forward
Integral to the success of the Syn-One Biomarker Services is the application of advanced immunofluorescence technology. This method enables visualization of synuclein in skin nerves, while CND’s AI-assisted digital pathology tool, NerValence™, leverages deep learning algorithms to deliver in-depth analysis of nerve structures and their pathological changes. This innovative approach marks a significant step forward in how researchers can study neurodegenerative diseases.
Future Applications of Syn-One Biomarker Services
As part of its ongoing research efforts, CND Life Sciences is expanding the application of Syn-One services in various clinical trials, including new studies aimed at tracking phosphorylated alpha-synuclein in patients with Parkinson's disease. The company has partnered with the Michael J. Fox Foundation to support these initiatives through the Syn-Q Study, which aims to refine biomarker testing methods further.
Expert Insights from CND Leadership
Dr. Christopher Gibbons, the Chief Scientific Officer at CND, expressed his enthusiasm over the preliminary data from the 201 Trial. He noted the positive implications these results have on the understanding of phosphorylated alpha-synuclein as a potential biomarker in clinical trials targeting Parkinson's disease and comparable conditions. He emphasized that while more extensive research is crucial, the data highlights Syn-One’s potential effectiveness in future trials.
About CND Life Sciences
CND Life Sciences plays a vital role in supporting patients potentially facing neurodegenerative disease diagnoses. The company operates a CLIA-certified lab that provides the Syn-One Test, designed to assist healthcare professionals in identifying various synucleinopathies, including Parkinson's disease and related conditions. The test has demonstrated a notable sensitivity rate in detecting these disorders, thus reinforcing its significance in clinical settings.
Frequently Asked Questions
What is the purpose of the Syn-One Biomarker Services?
The Syn-One Biomarker Services aim to accurately quantify and visualize phosphorylated alpha-synuclein in cutaneous nerves, facilitating better understanding of Parkinson's disease progression and treatment efficacy.
Who conducted the phase 2 trial involving Syn-One services?
The phase 2 trial, known as the 201 Trial, was conducted by ABLi Therapeutics, aiming to evaluate the effects of risvodetinib on phosphorylated alpha-synuclein levels.
What unique technologies does CND use in its biomarker analysis?
CND employs immunofluorescence technology alongside its AI-assisted digital pathology tool, NerValence™, to analyze nerve structures and detect abnormal synuclein deposits.
How does the Syn-One Test support Parkinson's disease diagnosis?
The Syn-One Test helps clinicians identify synucleinopathies by detecting phosphorylated alpha-synuclein in skin samples, aiding in the diagnostic evaluation of patients.
What future studies will CND Life Sciences be involved in?
CND is participating in the Syn-Q Study, supported by a grant from the Michael J. Fox Foundation, to further explore phosphorylated alpha-synuclein quantification in patients with Parkinson's disease over time.
